Core Viewpoint - Tongyun Biotechnology (01332) has seen a significant stock price increase of over 81%, reaching a peak of 0.75 HKD, which represents an almost 900% rise from the opening price of 0.076 HKD on October 30 [1] Company Summary - Tongyun Biotechnology is a wholly-owned subsidiary of Hong Kong-listed Tongyun Biotechnology Group, established in 2020 in Lucheng District, Shanxi Province, with an investment of 370 million HKD to build the world's first large-scale production facility for Rhizoclonium algae [1] - The company has a planned annual production capacity of 20,000 tons of Rhizoclonium algae powder, with the first phase of 4,000 tons having commenced production three months ahead of schedule in March 2023, utilizing a unique acetic acid fermentation process for automated production [1] Strategic Partnership - On October 24, Tongyun Biotechnology signed a strategic cooperation agreement with a sales consortium consisting of Shenzhen Building Supply Chain Technology Co., Ltd., Henan Guozi Marketing Management Co., Ltd., and Beijing He Wan Jia Biotechnology Co., Ltd. [1] - According to the agreement, the consortium will purchase no less than 1 billion HKD worth of Rhizoclonium algae products from Tongyun Biotechnology between 2026 and the end of 2028 [1]
透云生物再涨超81% 近三日累涨近9倍 山西透云生物签约10亿元莱茵衣藻订单